Friday, 07 March 2014
Dr Kariem Ezzat Ahmed and Dr Jyothis George have been appointed Robert Turner Research Associates at Green Templeton College.Dr Jyothis George is a clinical academic who trained at St John's Medical College (Bangalore) and obtained his PhD and specialist certification in diabetes, endocrinology and internal medicine in Edinburgh. He is now working on clinical trials and physiological studies of endocrinology at the Diabetes Trials Unit at the Oxford Centre for Diabetes, Endocrinology and Metabolism.
His research focus in Oxford is addressing the excess cardiovascular risk of people with diabetes, who are at least twice as likely as their healthy peers to develop cardiovascular complications such as strokes, heart attacks and amputations. He is also the lead clinician for a large-scale clinical outcome trial run by the Diabetes Trials Unit which is evaluating cardiovascular risk reduction in 14,000 patients from more than 30 countries using a novel once-weekly drug.
Dr Ahmed and Dr George will be members of GTC for a period of just under three terms until December 2014.
The Robert Turner Research Associate scholarship funds postgraduate physicians or scientists, visiting from abroad, who are already working in the field of diabetes or related disciplines in Oxford.
The scholarship was set up by GTC Associate Fellow Dr Jennie Turner in memory of her husband.
Dr George as mentioned above is the Principal Investigator for a Global study called EXSCEL.
The EXenatide Study of Cardiovascular Event Lowering (EXSCEL) clinical trial will find out if giving people with type 2 diabetes a drug called Exenatide alongside their usual diabetes care regime can reduce their risk of heart disease.
EXSCEL is a phase IIIb/IV multinational trial, being conducted in around 30 countries across Australasia, Asia, Europe, North America and Latin America.
Coordinated by DTU and Duke Clinical Research Institute (DCRI), and sponsored by Amylin Pharmaceuticals LLC, the trial began in June 2010.
14000 people with type 2 diabetes aged 18 years or older whose HbA1c is between 6.5% and 10% will be recruited to the trial. Each participant will receive an injection of Exenatide once a week, and will be followed for a minimum of four years.
We expect that results of this pragmatic trial (which aims to measure how beneficial a treatment would be in real clinical practice) will be available in 2018.